• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WIRB-Copernicus Group acquires New England IRB

WIRB-Copernicus Group acquires New England IRB

September 10, 2014
CenterWatch Staff

New England IRB (NEIRB) will become part of the growing group of recently acquired IRBs by WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services for clinical research.

The acquisition expands WCG’s presence in New England clinical research and further increases NEIRB’s expertise in all phases of drug, medical device and behavioral research. The purchase follows WCG’s acquisitions in June of Midlands IRB of Kansas City, Mo., and San Diego-based Aspire IRB.

Financial terms of all three deals were not disclosed.

“With NEIRB we get a leadership IRB with an outstanding reputation and regional presence and an east coast leader in the hot spot of the biotech industry—the Boston area,” said Donald A. Deieso, Ph.D., WCG chairman and CEO.

He said NEIRB, like WCG’s other acquisitions, will remain independent, keeping its name and leadership intact, but it will be able to accelerate growth with access to WCG’s information technology and capital resources, training, business and science expertise and expanded marketing and sales.

For James Saunders, NEIRB president, becoming part of WCG will enable the 26-year-old IRB to provide clients with greater access to technologies and processes to make clinical research more efficient.

For more details, read the upcoming issue of CWWeekly on Monday, Sept. 15.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing